DelveInsight’s ‘Dengue Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Dengue therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dengue pipeline domain.

For Dengue emerging drugs, the Dengue pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Request for Sample Page @ Dengue Pipeline Insight 2023

 

Key Takeaways from the Dengue Pipeline Report 

• DelveInsight’s Dengue Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment. 
• The leading Dengue companies include Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others are evaluating their lead assets to improve the Dengue treatment landscape.
• Key Dengue pipeline therapies in various stages of development include VIS 513, TAK-003, CDX DENV, AT 752, ABX 220, JNJ-64281802, TV003, Research programme: infectious diseases therapeutics, and others.
• In July 2023, Takeda said that it has voluntarily withdrawn its dengue vaccine application to the Food and Drug Administration, leaving it unclear when or if the vaccine would be licensed in the United States.
• In May 2023, the US Food and Drug Administration (FDA) granted Island Pharmaceuticals Ltd an Investigational New Drug (IND) approval and lifted a clinical hold on its ISLA-101 trial programme.

 

Request a sample and discover the recent breakthroughs happening in the Dengue pipeline landscape @ Dengue Pipeline Outlook

 

Dengue Overview

Dengue is a mosquito-borne virus that is the major cause of arthropod-borne viral disease worldwide. Because of the intensity of the muscular spasms and joint pain, it is often referred to as breakbone fever, dandy fever, or seven-day fever. Although the majority of cases are asymptomatic, severe disease and death are possible. Aedes mosquitos, which are abundant in tropical and subtropical areas around the world, transmit the virus. Dengue fever has spread substantially over the last few decades, and the disease is now endemic in various parts of the world. 

Mild dengue symptoms can be mistaken for other infections that produce fever, aches, and pains, or a rash. Fever with any of the following symptoms is the most prevalent symptom of dengue. Nausea, vomiting, rash, and aches and pains (usually behind the eyes, as well as muscular, joint, or bone pain). Many other infections might show similarly early in the disease phase, making clinical identification of dengue difficult.

 

Find out more about Dengue medication @ New Drug for Dengue 

 

Dengue Treatment Analysis: Drug Profile

VIS 513: Visterra

VIS513, a monoclonal antibody in development for the treatment of Dengue, a dangerous mosquito-borne virus that causes uncontrollable bleeding, organ failure, and death in its most severe forms. VIS513 is active against all four Dengue virus serotypes prevalent worldwide, both in vitro and in vivo.

 

TAK-003: Takeda

TAK-003, Takeda’s tetravalent dengue vaccine candidate, is based on a live-attenuated dengue serotype 2 virus that serves as the genetic “backbone” for all four vaccine viruses. TAK-003 induced immune responses against all four dengue serotypes in both seropositive and seronegative participants, which lasted for 48 months after vaccination, according to clinical Phase II data in children and adolescents, and the vaccine was found to be generally safe and well tolerated. The pivotal Phase 3 TIDES trial met its primary endpoint of overall vaccine efficacy (VE) against virologically confirmed dengue (VCD) at 12 months follow-up and all secondary endpoints with a sufficient number of dengue cases at 18 months follow-up, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals. TAK-003 was found to be generally well tolerated, with no significant safety hazards detected thus far. Takeda stated that the European Medicines Agency (EMA) has accepted the Company’s submission packages for its dengue vaccine candidate (TAK-003), which is being studied for the prevention of dengue caused by any dengue virus serotype in people aged four to 60.

 

Key Dengue Therapies and Companies

• VIS 513: Visterra
• TAK-003: Takeda
• CDX DENV: Codagenix
• AT 752: Atea Pharmaceuticals
• ABX 220: Abivax
• JNJ-64281802: Janssen Research & Development

 

Learn more about the novel and emerging Dengue pipeline therapies @ Dengue Clinical Trials

 

Dengue Therapeutics Assessment

By Product Type

• Monotherapy
• Combination Therapy

By Stage

• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type

• Oligonucleotide
• Peptide
• Small molecule

 

Scope of the Dengue Pipeline Report 

• Coverage: Global 

• Key Dengue Companies: Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.

• Key Dengue Pipeline Therapies: VIS 513, TAK-003, CDX DENV, AT 752, ABX 220, JNJ-64281802, TV003, Research programme: infectious diseases therapeutics, and others.

 

Dive deep into rich insights for drugs used for Dengue treatment; visit @ Dengue Drugs 

 

Table of Contents

1.	Introduction
2.	Executive Summary
3.	Dengue Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Dengue Pipeline Therapeutics
6.	Dengue Pipeline: Late Stage Products (Phase III)
7.	Dengue Pipeline: Late Stage Products (Phase III)
8.	Dengue Pipeline: Mid-Stage Products (Phase II)
9.	Dengue Pipeline: Early Stage Products (Phase  I)
10.	Therapeutic Assessment
11.	Inactive Products
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services